% | $
Quotes you view appear here for quick access.

Shire plc Message Board

  • zho10 zho10 Nov 8, 1998 7:06 AM Flag

    Galantamine takes 50% of Austrian market

    I happened accross this board by accident, and
    was surprised to see so few contributors given that
    45% of shares are now held in the US (figure correct
    at 3/98).

    I'm in the UK, and wondered if you
    had seen a news item reported here in a May edition
    of the Daily Mail newspaper. According to this,
    Galantamine (Reminyl) has been on sale in Austria since 1996
    following a small (N = 200) but promising clinical trial.
    It has already taken 50% of the market, and has
    knocked the previous leader, Pfizer's Aricept, down to
    40%. Worldwide, Aricept had sales of around �50m
    ($80m) in the last quarter, so if the Austrian situation
    were replicated world-wide this would have an enormous
    effect on SHPGY's turnover and profitability.

    SortNewest  |  Oldest  |  Most Replied Expand all replies